Physician

Mark Noble Schwendiman, D.O.

According to 2025 Medicare claims, Mark Schwendiman, D.O. (NPI: 1417184409) practices dermatology in the Boise City, ID market, with the plurality of this provider's patient population coming from Ada, ID. This provider's primary affiliated billing organization is ADA WEST DERMATOLOGY, PC (NPI: 1518973338; TIN: 20-3276415) and primary practice location at 83646-7128.

Schwendiman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 733 traditional Medicare patients, billed 4,407 HCPCS/CPT codes, and received $229,873 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,008 prescription claims across 449 beneficiaries totaling $121,953 in drug costs, led by Dupixent Syringe (Dupilumab). Open Payments data shows 79 records totaling $1,623. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $44,302 to $229,873. Similarly, Part D prescription costs have moved sharply higher in recent years, from $9,431 to $121,953. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	180	915	$44,302
2018	412	2,463	$105,088
2019	507	3,015	$155,516
2020	471	2,828	$155,719
2021	530	3,183	$174,206
2022	621	3,505	$193,677
2023	689	4,079	$214,840
2024	733	4,407	$229,873

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	67	100	$9,431
2018	221	433	$52,242
2019	259	514	$86,704
2020	274	605	$83,241
2021	350	747	$196,098
2022	383	814	$195,334
2023	436	972	$159,005
2024	449	1,008	$121,953

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17110	Destruction of skin growth, 1-14 growths	132	147	$81
11102	Biopsy of related skin growth, first growth	227	282	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	574	706	$56
17000	Destruction of precancer skin growth, 1 growth	377	547	$35
17003	Destruction of precancer skin growth, 2-14 growths	294	1,594	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	13	364	$48,148
Fluorouracil	Fluorouracil	54	1,537	$5,155
Triamcinolone Acetonide	Triamcinolone Acetonide	170	5,509	$3,259
Isotretinoin	Isotretinoin	17	510	$3,219
Doxycycline Hyclate	Doxycycline Hyclate	68	2,739	$2,144

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$1,623	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Noble Schwendiman, D.O.?

Tedicare shows public-source Medicare data for Mark Noble Schwendiman, D.O. (NPI 1417184409), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Noble Schwendiman, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Noble Schwendiman, D.O.?

Mark Noble Schwendiman, D.O. is linked to ADA WEST DERMATOLOGY, PC (billing NPI 1518973338) in the available physician profile data.

Does Mark Noble Schwendiman, D.O. have Open Payments data?

Mark Noble Schwendiman, D.O. has 79 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.